运载抗肿瘤药物的隐形纳米粒的研究进展

PLGA–mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties[J] . K Avgoustakis,A Beletsi,Z Panagi,P Klepetsanis,A.G Karydas,D.S Ithakissios.Journal of Controlled Release . 2002 (1)

Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: Influence of PEG coating on the particle size, drug release rate and phagocytic uptake[J] . Giacomo Fontana,Mariano Licciardi,Silvana Mansueto,Domenico Schillaci,Gaetano Giammona.Biomaterials . 2001 (21)

Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules[J] . Vanessa Carla Furtado Mosqueira,Philippe Legrand,Annette Gulik,Olivier Bourdon,Ruxandra Gref,Denis Labarre,Gillian Barratt.Biomaterials . 2001 (22)

Tumour targeted delivery of encapsulated dextran–doxorubicin conjugate using chitosan nanoparticles as carrier[J] . S Mitra,U Gaur,P.C Ghosh,A.N Maitra.Journal of Controlled Release . 2001 (1)

‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol （PEG）: influences of the corona （PEG chain length and surface density） and of the core composition on phagocytic uptake and plasma protein adsorption[J] . R Gref,M Lück,P Quellec,M Marchand,E Dellacherie,S Harnisch,T Blunk,R.H Müller.Colloids and Surfaces B: Biointerfaces . 2000 (3)

Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system[J] . Upasna Gaur,Sanjeeb Kumar Sahoo,Tapas K De,Prahlad C Ghosh,Amarnath Maitra,P.K Ghosh.International Journal of Pharmaceutics . 2000 (1)

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review[J] . H Maeda,J Wu,T Sawa,Y Matsumura,K Hori.Journal of Controlled Release . 2000 (1)

Visualization of in vitro protein-rejecting properties of PEGylated stealth ? polycyanoacrylate nanoparticles[J] . Biomaterials . 1999 (14)

PLGA–mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties[J] . K Avgoustakis,A Beletsi,Z Panagi,P Klepetsanis,A.G Karydas,D.S Ithakissios.Journal of Controlled Release . 2002 (1)

Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: Influence of PEG coating on the particle size, drug release rate and phagocytic uptake[J] . Giacomo Fontana,Mariano Licciardi,Silvana Mansueto,Domenico Schillaci,Gaetano Giammona.Biomaterials . 2001 (21)

Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules[J] . Vanessa Carla Furtado Mosqueira,Philippe Legrand,Annette Gulik,Olivier Bourdon,Ruxandra Gref,Denis Labarre,Gillian Barratt.Biomaterials . 2001 (22)

Tumour targeted delivery of encapsulated dextran–doxorubicin conjugate using chitosan nanoparticles as carrier[J] . S Mitra,U Gaur,P.C Ghosh,A.N Maitra.Journal of Controlled Release . 2001 (1)

‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol （PEG）: influences of the corona （PEG chain length and surface density） and of the core composition on phagocytic uptake and plasma protein adsorption[J] . R Gref,M Lück,P Quellec,M Marchand,E Dellacherie,S Harnisch,T Blunk,R.H Müller.Colloids and Surfaces B: Biointerfaces . 2000 (3)

Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system[J] . Upasna Gaur,Sanjeeb Kumar Sahoo,Tapas K De,Prahlad C Ghosh,Amarnath Maitra,P.K Ghosh.International Journal of Pharmaceutics . 2000 (1)

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review[J] . H Maeda,J Wu,T Sawa,Y Matsumura,K Hori.Journal of Controlled Release . 2000 (1)

Visualization of in vitro protein-rejecting properties of PEGylated stealth ? polycyanoacrylate nanoparticles[J] . Biomaterials . 1999 (14)